• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

作者信息

Han Ernest S, Monk Bradley J

出版信息

Gynecol Oncol. 2007 Apr;105(1):3-6. doi: 10.1016/j.ygyno.2007.01.038.

DOI:10.1016/j.ygyno.2007.01.038
PMID:17383545
Abstract
摘要

相似文献

1
What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?贝伐单抗治疗卵巢癌时肠道穿孔的风险有多大？
Gynecol Oncol. 2007 Apr;105(1):3-6. doi: 10.1016/j.ygyno.2007.01.038.
2
Bevacizumab in the treatment of ovarian cancer.贝伐单抗治疗卵巢癌。
Expert Rev Anticancer Ther. 2007 Oct;7(10):1339-45. doi: 10.1586/14737140.7.10.1339.
3
Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer.
Gynecol Oncol. 2009 Nov;115(2):308-9. doi: 10.1016/j.ygyno.2009.08.003. Epub 2009 Sep 8.
4
Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?哪些因素可预测接受贝伐珠单抗治疗的复发性上皮性卵巢癌患者的肠道并发症？
Gynecol Oncol. 2010 Jul;118(1):47-51. doi: 10.1016/j.ygyno.2010.01.011. Epub 2010 Apr 10.
5
[Surgical management of bevacizumab-associated peritonitis due to perforation].[贝伐单抗相关穿孔性腹膜炎的手术治疗]
Zentralbl Chir. 2009 Sep;134(5):462-7. doi: 10.1055/s-0028-1098701. Epub 2009 Sep 15.
6
Bevacizumab toxicities and their management in ovarian cancer.贝伐珠单抗在卵巢癌中的毒性及其处理。
Gynecol Oncol. 2010 Jun;117(3):497-504. doi: 10.1016/j.ygyno.2010.02.021. Epub 2010 Apr 2.
7
Bevacizumab-induced bowel perforation.贝伐单抗引起的肠穿孔。
J Am Osteopath Assoc. 2011 Jul;111(7):437-41.
8
Success of bevacizumab trials raises questions for future studies.贝伐单抗试验的成功给未来的研究提出了问题。
J Natl Cancer Inst. 2005 Jul 6;97(13):950-1. doi: 10.1093/jnci/dji194.
9
[Generation mechanisms and management strategies of adverse reactions to Bevacizumab during cancer treatment].[癌症治疗期间贝伐单抗不良反应的发生机制及管理策略]
Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):481-6.
10
Angiogenesis as a strategic target for ovarian cancer therapy.血管生成作为卵巢癌治疗的一个战略靶点。
Nat Clin Pract Oncol. 2008 Apr;5(4):194-204. doi: 10.1038/ncponc1051. Epub 2008 Feb 12.

引用本文的文献

1
Safety Analysis of Bevacizumab in Ovarian Cancer Patients.贝伐单抗在卵巢癌患者中的安全性分析。
J Clin Med. 2023 Mar 6;12(5):2065. doi: 10.3390/jcm12052065.
2
Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first-line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database.贝伐珠单抗联合新辅助化疗作为晚期卵巢、输卵管或腹膜癌一线治疗相关胃肠道穿孔的发生率：日本医保索赔数据库分析。
J Gynecol Oncol. 2022 Nov;33(6):e78. doi: 10.3802/jgo.2022.33.e78. Epub 2022 Sep 30.
3
A case report of vesicovaginal fistula following Bevacizumab without pelvic disease and radiochemotherapy.
贝伐单抗治疗且无盆腔疾病及放化疗后发生膀胱阴道瘘的病例报告
Transl Cancer Res. 2022 Aug;11(8):2936-2939. doi: 10.21037/tcr-22-251.
4
Metastatic osteosarcoma bowel perforation secondary to chemotherapy-induced tumour necrosis.化疗诱导肿瘤坏死继发转移性骨肉瘤肠穿孔。
BMJ Case Rep. 2022 Apr 26;15(4):e247774. doi: 10.1136/bcr-2021-247774.
5
Chemotherapy-induced bowel ischemia: diagnostic imaging overview.化疗诱导的肠缺血：诊断成像概述。
Abdom Radiol (NY). 2022 May;47(5):1556-1564. doi: 10.1007/s00261-021-03024-9. Epub 2021 Apr 3.
6
Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer.一名接受贝伐单抗治疗卵巢癌的患者发生中性粒细胞减少性小肠结肠炎所致的肠穿孔。
Case Rep Oncol Med. 2020 Jun 16;2020:7231358. doi: 10.1155/2020/7231358. eCollection 2020.
7
Spontaneous massive duodenal perforation after ovarian cancer treatment with bevacizumab.使用贝伐单抗治疗卵巢癌后发生的自发性十二指肠巨大穿孔。
J Surg Case Rep. 2020 Jun 19;2020(6):rjaa174. doi: 10.1093/jscr/rjaa174. eCollection 2020 Jun.
8
Bowel Perforation in the Emergency Department Related to Bevacizumab Therapy and Recurrent Ovarian Cancer.急诊科与贝伐单抗治疗及复发性卵巢癌相关的肠穿孔
Clin Pract Cases Emerg Med. 2020 Mar 27;4(2):227-229. doi: 10.5811/cpcem.2020.1.45374. eCollection 2020 May.
9
Application Of Adoptive Immunotherapy In Ovarian Cancer.过继性免疫疗法在卵巢癌中的应用
Onco Targets Ther. 2019 Sep 27;12:7975-7991. doi: 10.2147/OTT.S221773. eCollection 2019.
10
Recurrent colon perforation after discontinuation of bevacizumab for ovarian cancer.贝伐单抗停用后复发性结肠癌穿孔用于卵巢癌治疗。 （此译文表述稍显生硬，建议优化为：贝伐单抗停用后卵巢癌患者出现复发性结肠穿孔 ）
Gynecol Oncol Rep. 2018 Aug 24;26:21-23. doi: 10.1016/j.gore.2018.08.005. eCollection 2018 Nov.